Instem to use IPO funds to augment drug safety offering

Instem Life Science Systems, maker of early development safety assessment software, says it will use cash raised in its initial public offering in London to increase its appeal to big pharma. On the radar: acquisitions that target software makers whose product capabilities complement its own. Efficacy and drug behavior in the body are examples. The strategy is to capitalize on the needs of drug developers facing a fragmented solutions supplier community. Article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.